A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression

Induction of immunity after DNA vaccination is generally considered a slow process. Here we show that DNA delivery to the skin results in a highly transient pulse of antigen expression. Based on this information, we developed a new rapid and potent intradermal DNA vaccination method. By short-interval intradermal DNA delivery, robust T-cell responses, of a magnitude sufficient to reject established subcutaneous tumors, are generated within 12 d. Moreover, this vaccination strategy confers protecting humoral immunity against influenza A infection within 2 weeks after the start of vaccination. The strength and speed of this newly developed strategy will be beneficial in situations in which immunity is required in the shortest possible time.

[1]  S. Hoffman,et al.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. , 1998, Science.

[2]  P. Musiani,et al.  LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. , 2003, Cancer research.

[3]  C. Blank,et al.  CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants , 1997, European journal of immunology.

[4]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[5]  T. Schumacher,et al.  Optimizing the Efficacy of Epitope-Directed DNA Vaccination1 , 2002, The Journal of Immunology.

[6]  P. Scherle,et al.  Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. , 1992, Journal of immunology.

[7]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[8]  R. Jaenisch,et al.  Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells , 1991, The Journal of experimental medicine.

[9]  D. Kioussis,et al.  Positive and Negative Selection in Transgenic Mice Expressing a T-Cell Receptor Specific for Influenza Nucleoprotein and Endogenous Superantigen , 1993, Developmental immunology.

[10]  Freda K. Stevenson,et al.  Critical Components of a DNA Fusion Vaccine Able to Induce Protective Cytotoxic T Cells Against a Single Epitope of a Tumor Antigen1 , 2002, The Journal of Immunology.

[11]  B. Murphy,et al.  Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. , 1993, Journal of immunology.

[12]  S. Hoffman,et al.  Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Carbone,et al.  Puncture-mediated gene transfer to the skin. , 1996, Human gene therapy.

[14]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[15]  J. Virelizier,et al.  Host defenses against influenza virus: the role of anti-hemagglutinin antibody. , 1975, Journal of immunology.

[16]  J. Belisle,et al.  Enhanced Immunogenicity to Mycobacterium tuberculosis by Vaccination with an Alphavirus Plasmid Replicon Expressing Antigen 85A , 2003, Infection and Immunity.

[17]  S. Schüller,et al.  In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. , 2002, Cancer research.

[18]  R. Koup,et al.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates , 2003, Nature.

[19]  A. Sanchez,et al.  Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.

[20]  P. Liljeström,et al.  Non-viral amplification systems for gene transfer: vectors based on alphaviruses. , 1999, Current opinion in molecular therapeutics.

[21]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[22]  A. Venuti,et al.  DNA vaccines against HPV-16 E7-expressing tumour cells. , 2003, Anticancer research.

[23]  T. Schumacher,et al.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.

[24]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[25]  S. Gurunathan,et al.  DNA vaccines: immunology, application, and optimization*. , 2000, Annual review of immunology.

[26]  T. Wu,et al.  Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. , 2000, Cancer research.